Stock Track | Tandem Diabetes Care Plummets 33.6% as Disappointing Outlook and Sales Forecast Spook Investors

Stock Track

Feb 27

Shares of Tandem Diabetes Care (TNDM) plunged a staggering 33.6% in pre-market trading on Thursday, following the company's weaker-than-expected fourth-quarter results and a gloomy outlook for the current fiscal year.

The medical device maker reported an adjusted operating loss of $30.2 million for Q4, significantly wider than analysts' estimate of a $17.6 million loss. Additionally, the adjusted net loss for the quarter stood at $28.8 million, missing the consensus estimate of a $14.9 million loss. The disappointing results were primarily driven by weaker-than-expected sales and higher costs.

Exacerbating the investor concerns, Tandem Diabetes Care provided a lackluster outlook for 2025, forecasting an adjusted net loss of $1.20 per share on revenue of $1.01 billion. This guidance fell short of analysts' projections, with the revenue forecast being largely flat compared to the previous year. The company cited "muted seasonality" and "shipping delays" as factors that led to softness in demand for its insulin pumps towards the end of Q4, and expects salesforce disruptions to continue impacting the business.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1119936037"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119936037\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1119936037?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 23:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119936037","market":"us","top_or_hot":-1,"title":"Stock Track | Tandem Diabetes Care Plummets 33.6% as Disappointing Outlook and Sales Forecast Spook Investors","media":"Stock Track","content":"<p>Shares of Tandem Diabetes Care (TNDM) plunged a staggering 33.6% in pre-market trading on Thursday, following the company's weaker-than-expected fourth-quarter results and a gloomy outlook for the current fiscal year.</p>\n\n<p>The medical device maker reported an adjusted operating loss of $30.2 million for Q4, significantly wider than analysts' estimate of a $17.6 million loss. Additionally, the adjusted net loss for the quarter stood at $28.8 million, missing the consensus estimate of a $14.9 million loss. The disappointing results were primarily driven by weaker-than-expected sales and higher costs.</p>\n\n<p>Exacerbating the investor concerns, Tandem Diabetes Care provided a lackluster outlook for 2025, forecasting an adjusted net loss of $1.20 per share on revenue of $1.01 billion. This guidance fell short of analysts' projections, with the revenue forecast being largely flat compared to the previous year. The company cited \"muted seasonality\" and \"shipping delays\" as factors that led to softness in demand for its insulin pumps towards the end of Q4, and expects salesforce disruptions to continue impacting the business.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tandem Diabetes Care Plummets 33.6% as Disappointing Outlook and Sales Forecast Spook Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tandem Diabetes Care Plummets 33.6% as Disappointing Outlook and Sales Forecast Spook Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-27 23:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Tandem Diabetes Care (TNDM) plunged a staggering 33.6% in pre-market trading on Thursday, following the company's weaker-than-expected fourth-quarter results and a gloomy outlook for the current fiscal year.</p>\n\n<p>The medical device maker reported an adjusted operating loss of $30.2 million for Q4, significantly wider than analysts' estimate of a $17.6 million loss. Additionally, the adjusted net loss for the quarter stood at $28.8 million, missing the consensus estimate of a $14.9 million loss. The disappointing results were primarily driven by weaker-than-expected sales and higher costs.</p>\n\n<p>Exacerbating the investor concerns, Tandem Diabetes Care provided a lackluster outlook for 2025, forecasting an adjusted net loss of $1.20 per share on revenue of $1.01 billion. This guidance fell short of analysts' projections, with the revenue forecast being largely flat compared to the previous year. The company cited \"muted seasonality\" and \"shipping delays\" as factors that led to softness in demand for its insulin pumps towards the end of Q4, and expects salesforce disruptions to continue impacting the business.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNDM","symbol_name":"Tandem Diabetes","start_time":0,"source_url":"","article_id":"1119936037","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119936037","pubTimestamp":1740668888,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Tandem Diabetes Care  plunged a staggering 33.6% in pre-market trading on Thursday, following the company's weaker-than-expected fourth-quarter results and a gloomy outlook for the current fiscal year.The medical device maker reported an adjusted operating loss of $30.2 million for Q4, significantly wider than analysts' estimate of a $17.6 million loss. Additionally, the adjusted net loss for the quarter stood at $28.8 million, missing the consensus estimate of a $14.9 million loss. Th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNDM":"Tandem Diabetes"},"translate_title":"由于令人失望的前景和销售预测令投资者感到恐慌，Tandem Diabetes Care股价暴跌33.6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNDM":1},"content_text":"Shares of Tandem Diabetes Care (TNDM) plunged a staggering 33.6% in pre-market trading on Thursday, following the company's weaker-than-expected fourth-quarter results and a gloomy outlook for the current fiscal year.\nThe medical device maker reported an adjusted operating loss of $30.2 million for Q4, significantly wider than analysts' estimate of a $17.6 million loss. Additionally, the adjusted net loss for the quarter stood at $28.8 million, missing the consensus estimate of a $14.9 million loss. The disappointing results were primarily driven by weaker-than-expected sales and higher costs.\nExacerbating the investor concerns, Tandem Diabetes Care provided a lackluster outlook for 2025, forecasting an adjusted net loss of $1.20 per share on revenue of $1.01 billion. This guidance fell short of analysts' projections, with the revenue forecast being largely flat compared to the previous year. The company cited \"muted seasonality\" and \"shipping delays\" as factors that led to softness in demand for its insulin pumps towards the end of Q4, and expects salesforce disruptions to continue impacting the business.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}